Gemtuzumab ozogamicin is efficacious in attaining complete remission in relapsed/refractory acute leukemia prior to hematopoietic cell transplant: A case series.
作者信息
Fatobene Giancarlo, Souza Gabriela Rodriguez de, Rodrigues Celso Arrais, Novis Yana Augusta Sarkis, Rocha Vanderson
机构信息
Sírio-Libanês Hospital, São Paulo, SP, Brazil; Instituto do Câncer do Estado de São Paulo da Universidade de São Paulo (ICESP USP), São Paulo, SP, Brazil; Laboratório Investigação Médica em Patogênese e Terapia dirigida em Onco-Imuno-Hematologia do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (LIM/31 HCFMUSP), São Paulo, SP, Brazil.
Sírio-Libanês Hospital, São Paulo, SP, Brazil.
出版信息
Hematol Transfus Cell Ther. 2021 Oct-Dec;43(4):532-536. doi: 10.1016/j.htct.2020.07.008. Epub 2020 Sep 13.
Abstract
摘要
相似文献
1
Gemtuzumab ozogamicin is efficacious in attaining complete remission in relapsed/refractory acute leukemia prior to hematopoietic cell transplant: A case series.
Hematol Transfus Cell Ther. 2021 Oct-Dec;43(4):532-536. doi: 10.1016/j.htct.2020.07.008. Epub 2020 Sep 13.
2
Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study.
Haematologica. 2014 Jan;99(1):54-9. doi: 10.3324/haematol.2013.096545. Epub 2013 Oct 18.
3
Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure.
Biology (Basel). 2020 Feb 10;9(2):28. doi: 10.3390/biology9020028.
4
Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.
Blood. 2005 Aug 15;106(4):1183-8. doi: 10.1182/blood-2004-10-3821. Epub 2005 May 10.
5
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Clin Cancer Res. 2001 Jun;7(6):1490-6.
6
Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia.
Biol Blood Marrow Transplant. 2019 Sep;25(9):1720-1729. doi: 10.1016/j.bbmt.2019.04.020. Epub 2019 Apr 27.
7
Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group.
Haematologica. 2019 Jan;104(1):120-127. doi: 10.3324/haematol.2018.191841. Epub 2018 Aug 9.
8
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
Clin Lymphoma Myeloma Leuk. 2012 Aug;12(4):244-51. doi: 10.1016/j.clml.2012.03.003. Epub 2012 Apr 24.
9
Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia.
Expert Rev Anticancer Ther. 2002 Dec;2(6):630-40. doi: 10.1586/14737140.2.6.630.
10
Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia.
Clin Lymphoma. 2002 Mar;2 Suppl 1:S24-8. doi: 10.3816/clm.2002.s.005.
引用本文的文献
1
Development, efficacy and side effects of antibody‑drug conjugates for cancer therapy (Review).
Mol Clin Oncol. 2023 May 4;18(6):47. doi: 10.3892/mco.2023.2643. eCollection 2023 Jun.
本文引用的文献
1
The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia.
Oncologist. 2019 May;24(5):e171-e179. doi: 10.1634/theoncologist.2019-0025. Epub 2019 Mar 21.
2
Gemtuzumab ozogamicin in acute myeloid leukemia: act 2, with perhaps more to come.
Haematologica. 2019 Jan;104(1):7-9. doi: 10.3324/haematol.2018.205948.
3
Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review.
Ann Hematol. 2018 Jul;97(7):1115-1153. doi: 10.1007/s00277-018-3304-y. Epub 2018 Apr 21.
4
Salvage therapy for relapsed or refractory acute myeloid leukemia.
Ther Adv Hematol. 2011 Apr;2(2):73-82. doi: 10.1177/2040620711402533.
5
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.
Lancet. 2012 Apr 21;379(9825):1508-16. doi: 10.1016/S0140-6736(12)60485-1. Epub 2012 Apr 5.
6
Large interindividual differences in cellular sensitivity to calicheamicin may influence gemtuzumab ozogamicin response in acute myeloid leukemia.
Leukemia. 2008 Dec;22(12):2284-5. doi: 10.1038/leu.2008.147. Epub 2008 Jun 19.
7
High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group.
Leukemia. 2007 Jan;21(1):66-71. doi: 10.1038/sj.leu.2404434. Epub 2006 Oct 19.
8
Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin.
Leukemia. 2003 Feb;17(2):468-70. doi: 10.1038/sj.leu.2402749.
9
Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia.
Cancer Chemother Pharmacol. 2002 Dec;50(6):497-500. doi: 10.1007/s00280-002-0539-y. Epub 2002 Oct 22.
Zotero 插件